Cellectar stockholders approve increase in share reserve by 7M shares, re-elect directors

Cellectar Biosciences, Inc.

Stockholders approved amendment to 2021 Stock Incentive Plan, increasing shares reserved by 7,000,000 (14.5M for, 1.06M against).
Class I directors Asher Chanan-Khan and John Neis re-elected with 15.4M and 14.9M votes for, respectively.
Ratification of Baker Tilly US, LLP as independent auditor for FY2024 approved (25.8M for, 183k against).
Non-binding advisory vote on executive compensation approved (15.1M for, 436k against).
No departures or other material changes reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.